Eisai Company, Limited

Yukio Ohya

Yoshimasa Machida

Shigeto Negi

Isao Saito

Seiichiro Nomoto

Kyosuke Kitoh

Kentaro Yoshimatsu

Kanemasa Katsu

Toshio Osawa

Isao Tanaka

Yoshikazu Hasegawa

Toshio Seto

Yasushi Shikata

Takeshi Suzuki

Motosuke Yamanaka

Takeshi Nagasu

Takeo Kanai

Kyoko Koizumi

A recombinant natural killer cell activating factor is disclosed, preferably having a peptide of the following amino acid sequence in its molecule. The invention provides a cDNA coding for a recombinant natural killer cell activating factor, a expression plasmid involving the cDNA, a host transformed with the plasmid, an antitumor agent containing the recombinant natural killer cell activating factor and a pharmaceutical composition which comprises a pharmacologically effective amount of the antitumor agent and a pharmacologically acceptable carrier.

Recombinant natural killer cell activator

Novel cephalosporin compounds of the general formula: ##STR1## wherein R.sub.1 represents a substituted or unsubstituted nitrogen-containing heterocyclic-thio group, R.sub.2 represents hydrogen or hydroxy, and R.sub.3, R.sub.4 and R.sub.5 each represents hydrogen, hydroxy or acyloxy, and their salts, and processes for the preparation thereof. The novel compounds and their salts have antibacterial activity.

Cephalosporin compounds and antibacterial drugs containing the same

New cephalosporin derivatives represented by the general formula: ##STR1## wherein R.sub.1, R.sub.2, and R.sub.3 each represents hydroxy, acyloxy, and hydrogen provided that two or three of R.sub.1, R.sub.2, and R.sub.3 are not hydrogen at the same time, and their salts, and processes for the preparation thereof. The cephalosporin derivatives of the present invention are useful as antibacterial drugs.

Cephalosporin derivatives, and antibacterial drugs containing the

Growing community of inventors

Ibaraki, Japan

Yukio Ohya